186 related articles for article (PubMed ID: 17006704)
1. Does cyclically iloprost infusion prevent severe isolated pulmonary hypertension in systemic sclerosis? Preliminary results.
Caramaschi P; Volpe A; Tinazzi I; Bambara LM; Carletto A; Biasi D
Rheumatol Int; 2006 Dec; 27(2):203-5. PubMed ID: 17006704
[TBL] [Abstract][Full Text] [Related]
2. Long-term evaluation of lung function in patients affected by scleroderma treated with cyclic iloprost infusions.
Caramaschi P; Biasi D; Ferrari M; Volpe A; Martinelli N; Carletto A; Dal Forno P; Bambara LM
Rheumatol Int; 2005 May; 25(4):250-4. PubMed ID: 14963694
[TBL] [Abstract][Full Text] [Related]
3. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis.
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbruck B; Grimminger F; Seeger W
Am J Respir Crit Care Med; 1999 Aug; 160(2):600-7. PubMed ID: 10430735
[TBL] [Abstract][Full Text] [Related]
4. Severe vascular complications in patients affected by systemic sclerosis cyclically treated with iloprost.
Caramaschi P; Dalla Gassa A; Prati D; Barausse G; Tinazzi I; Ravagnani V; Confente S; Biasi D
Rheumatol Int; 2012 Jul; 32(7):1933-8. PubMed ID: 21448643
[TBL] [Abstract][Full Text] [Related]
5. Intermittent iloprost infusion therapy of pulmonary hypertension in scleroderma--a pilot study.
Bartosik I; Eskilsson J; Scheja A; Akesson A
Br J Rheumatol; 1996 Nov; 35(11):1187-8. PubMed ID: 8948314
[No Abstract] [Full Text] [Related]
6. [Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to pulmonary fibrosis].
Olschewski H; Ghofrani HA; Walmrath D; Schermuly R; Temmesfeld-Wollbrück B; Grimminger F; Seeger W
Pneumologie; 2000 Mar; 54(3):133-42. PubMed ID: 10783653
[TBL] [Abstract][Full Text] [Related]
7. Sustained success of therapy with inhaled iloprost for severe pulmonary arterial hypertension associated with systemic sclerosis and pulmonary fibrosis.
Ahmadi-Simab K; Köhler A; Gross WL
Clin Exp Rheumatol; 2007; 25(5):760-2. PubMed ID: 18078629
[TBL] [Abstract][Full Text] [Related]
8. Long-term clinical stabilization of scleroderma patients treated with a chronic and intensive IV iloprost regimen.
Foti R; Visalli E; Amato G; Benenati A; Converso G; Farina A; Bellofiore S; Mulè M; Di Gangi M
Rheumatol Int; 2017 Feb; 37(2):245-249. PubMed ID: 27796521
[TBL] [Abstract][Full Text] [Related]
9. Aerosolized iloprost in CREST syndrome related pulmonary hypertension.
Launay D; Hachulla E; Hatron PY; Goullard L; Onimus T; Robin S; Fauchais AL; Queyrel V; Michon-Pasturel U; Hebbar M; Saulnier F; Devulder B
J Rheumatol; 2001 Oct; 28(10):2252-6. PubMed ID: 11669165
[TBL] [Abstract][Full Text] [Related]
10. Long-term effects of intermittent Iloprost infusion on pulmonary arterial pressure in connective tissue disease.
Caravita S; Wu SC; Secchi MB; Dadone V; Bencini C; Pierini S
Eur J Intern Med; 2011 Oct; 22(5):518-21. PubMed ID: 21925064
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary hypertension secondary to systemic lupus erythematosus: prolonged survival following treatment with intermittent low dose iloprost.
Mok MY; Tse HF; Lau CS
Lupus; 1999; 8(4):328-31. PubMed ID: 10413214
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the usage of intravenous iloprost and nitroglycerin for pulmonary hypertension during valvular heart surgery.
Baysal A; Bilsel S; Bulbul OG; Kayacioglu I; Idiz M; Yekeler I
Heart Surg Forum; 2006; 9(1):E536-42. PubMed ID: 16387672
[TBL] [Abstract][Full Text] [Related]
13. [Clinical and hemodynamic characteristics and possibilities for therapy in patients with severe (functional class IV) pulmonary arterial hypertension associated with diffuse connective tissue diseases].
Nikolaeva EV; Yudkina NN; Kurmukov IA; Novikova DS; Markelova EI; Volkov AV
Ter Arkh; 2015; 87(5):24-32. PubMed ID: 26155616
[TBL] [Abstract][Full Text] [Related]
14. Exhaled nitric oxide and pulmonary response to iloprost in systemic sclerosis with pulmonary hypertension.
Rolla G; Colagrande P; Brussino L; Bucca C; Bertero MT; Caligaris-Cappio F
Lancet; 1998 May; 351(9114):1491-2. PubMed ID: 9605813
[No Abstract] [Full Text] [Related]
15. Comparison of acute hemodynamic effects of aerosolized and intravenous iloprost in secondary pulmonary hypertension in children with congenital heart disease.
Hallioglu O; Dilber E; Celiker A
Am J Cardiol; 2003 Oct; 92(8):1007-9. PubMed ID: 14556887
[TBL] [Abstract][Full Text] [Related]
16. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.
Airò P; Rossi M; Scarsi M; Danieli E; Grottolo A; Zambruni A
Clin Exp Rheumatol; 2007; 25(5):722-7. PubMed ID: 18078620
[TBL] [Abstract][Full Text] [Related]
17. A case of diffuse systemic sclerosis treated with a 28-day infusion of iloprost.
Biasi D; Caramaschi P; Carletto A; Zeminian S; Schiavon F; Bambara LM
Clin Rheumatol; 1997 Jan; 16(1):111-2. PubMed ID: 9132317
[No Abstract] [Full Text] [Related]
18. Iloprost infusion does not reduce oxidative stress in systemic sclerosis.
Volpe A; Biasi D; Caramaschi P; Bambara LM; Carletto A; Degan M; Minuz P
Rheumatol Int; 2008 Feb; 28(4):335-7. PubMed ID: 17704920
[TBL] [Abstract][Full Text] [Related]
19. Combination therapy of prostacyclin for pulmonary hypertension in congenital heart disease.
Durongpisitkul K; Jakrapanichakul D; Laohaprasitiporn D; Soongswang J; Chanthong P; Nana A
J Med Assoc Thai; 2005 Nov; 88 Suppl 8():S60-5. PubMed ID: 16856428
[TBL] [Abstract][Full Text] [Related]
20. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension.
Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM
J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
